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AmfAR The Foundation for AIDS Research 
ATU  AIDS Treatment Update (Nam publication, later HIV Treatment Update) 
AZT  Zidovudine 
CD4  CD4 count is taken as an indicator of the strength of the immune system 
DDI  Didanosine (trade name: Videx) 
DoH  Department of Health 
EMA  European Medicines Agency 
GMFA  GMFA - The Gay Mens Health Charity (previously Gay Men Fighting AIDS) 
IAPAC International Association of Providers of AIDS Care 
IAS  International AIDS Society 
KS  Kaposi’s Sarcoma 
MRC  Medical Research Council 
MSM  Men who have sex with men 
NAM HIV organisation providing information and resources online at aidsmap.com 
(previously National AIDS Manual) 
NAT  National AIDS Trust 
PI   Protease Inhibitor 
PPI  Public Patient Involvement 
PrEP  Pre-exposure Prophylaxis 
RCT  Randomised Control Trial 
TasP  Treatment as Prevention 
TDM  Therapeutic Drug Monitoring 
THT   Terrence Higgins Trust 
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U=U Undetectable = Untransmittable (a community-based campaign to ensure the 
individual prevention benefit of treatment is recognised and understood at all 
levels of society) 
UNAIDS The Joint United Nations Programme on HIV/AIDS 
Viral Load A measure of the amount of HIV detectable in a sample of blood 
WHO  World Health Organisation 
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BACKGROUND TO THE WITNESS SEMINAR SERIES  
 
As convenors of the seminar and editors of this text, we would like to offer some background 
to our decision to conduct witness seminars aimed at enhancing historical understandings of 
the HIV/AIDS epidemic in the UK. Included in this background is an account of how they were 
organised and who we approached to participate.  
This witness seminar, ‘Antiretroviral Drugs up to and Including Treatment as Prevention (TasP) 
and Pre-Exposure Prophylaxis (PrEP) in the UK’ was the first in the series for the UK 
component of ‘Disentangling European HIV/AIDS Policies: Activism, Citizenship and Health’ 
(EUROPACH), funded by the Humanities in the European Research Area (HERA).  
Our decision to employ the mode of a ‘witness seminar’ was inspired, in part, by a meeting 
with the Advisory Committee that we assembled for the UK research. We had intended to use 
this meeting as an opportunity to present the project and our work so far to advisory committee 
members and to ask for advice and feedback. However, what emerged was not a simple two-
way dialogue where we asked for advice and they gave it, but instead a space in which all of 
the members of our advisory committee drew on their experiences and expertise, bounced off 
one another, and told us far more than we might ever have thought to ask them.  
One of us had already consulted some of the witness seminar transcripts produced by the 
History of Modern Biomedicine Research Group based at Queen Mary, University of London 
and available through the Wellcome Library. What was immediately apparent in these 
transcripts was their ability to capture both technical and specialist knowledge about particular 
health issues, but also that the issues were made readable and comprehendible to someone with 
little knowledge of the topic at hand. Although our witness seminars take a different format, we 
hope similarly that the resulting texts will shed light on some of the complexities of the history 
of HIV/AIDS.  
Having already considered the possibility of using the method ourselves and then being part of 
the lively space that emerged in our advisory committee meeting, we decided to hold the witness 
seminars in order to provide a history or, rather, histories of the UK HIV/AIDS epidemic, 
reflective of different perspectives, tensions and personal experiences. The resulting text from 
this seminar sits alongside oral history interviews undertaken as part of the EUROPACH project 
and other witness seminars undertaken during the course of our research. By contrast with the 
personal narratives provided by our one-to-one interviews, we have sought to create a space in 
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which people from different backgrounds and with different experiences of the epidemic could 
come together and tell their stories in conversation with others. As such, the personal narrative 
is still present within the witness seminar transcripts, but this is in conversation with others’ 
experiences and has thus resulted in a mode of collective retelling. 
Although we were inspired by the witness seminar transcripts we had already consulted, we 
decided to undertake this work in a manner attuned to our prior familiarity with the HIV 
epidemic and the manner in which many of those invited were well-versed in discussion about 
historical dimensions of the epidemic.  The more conventional witness seminar design often 
asks participants to prepare presentations in advance. Bearing in mind our participants 
experience in collaborative discussions and conscious that those we had invited would be better 
placed to decide on what was relevant, we did not specify any prior preparation. Nor did we 
ask for any style of presentation. In sum, we prioritised cultivating an open forum where a 
dialogue would emerge between participants who in same cases were already familiar with each 
other and in other cases not. Nevertheless, it was necessary to provide a starting point and for 
this reason we circulated a list of topics for possible discussion a couple of weeks before the 
meeting (see Appendix). 
SEMINAR INFORMATION  
Some of the participants in this witness seminar were already known to us through our own 
engagements in HIV and our knowledge of their contribution, while others were invited on the 
recommendation of those we had already approached. As mentioned above, we circulated a list 
of proposed topics for discussion a couple of weeks before the seminar, but made clear that we 
would welcome diversions from this list. 
 
The seminar Antiretroviral Drugs up to and Including the Proposition of TasP and PrEP in the 
UK was held in a meeting room in International Hall in London on 23rd November 2017 and 
was scheduled to run for two hours but ran over for an extra half an hour. Some participants 
left during the last half hour. During the seminar, audio recordings were made, which were then 
transcribed and edited in order to enable a clear reading of the text. Footnotes were then added 
and the text was circulated to participants with an invitation to further edit, redact or expand on 
their contributions. All participants signed consent forms agreeing to make the final transcript 
available for public viewing once they had been given the opportunity to edit or redact their 
contributions. 
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ANTIRETROVIRAL DRUGS UP TO AND INCLUDING THE PROPOSITION OF TASP  
AND PREP  IN THE UK 
 
Although we circulated a list of chronologically organised proposed topics a couple of weeks 
before this witness seminar, the meeting did not result in a chronological account. What 
emerged instead was a more topological pattern of engagement, whereby some of the early 
issues were connected with those of a more recent nature and, in turn, reconnected to develop 
a richer perspective on the earlier time. Antiretroviral medications were discussed not only in 
terms of their development or the ways in which they changed what it meant to be diagnosed 
with HIV. Rather, the discussion included some of the antagonisms, difficulties and broader 
changes which have accompanied the current drug prevention and treatment, while not 
forgetting the difficulties endured with early drug therapies including monotherapies. And often 
issues relating to but not necessarily limited to the history of antiretroviral medications were 
discussed. 
Indeed, the transcript of the seminar brings into view issues of care where, for example, 
activists offered to protest about a lack of space for a clinician; how modes of  caring for 
patients changed in the context of effective treatments; and how notions of certainty and 
uncertainty had to be navigated with the introduction of effective treatments. References were 
made to other health issues; how HIV changed certain styles of medical practice and new forms 
of patient involvement; how the recent discourse around the issue of PrEP might be likened to 
the discussions surrounding the introduction of the contraceptive pill in the 1960’s. HIV 
activism was discussed in terms of and in reference to the women’s liberation movement and 
broader LGBT politics. Notions of responsibility; the necessity of understanding the difference 
between thinking of treatments in relation to individual needs, and, in contrast, to public health 
policy. These are just some of the issues raised in the course of our discussion and, as such, 
provide  a complex account wherein antiretroviral medications can be seen as being implicated 
in various sets of relationships and alluding to many more histories of the epidemic that extend 
beyond a focus on the infection of HIV.    
The seminar began with a brief description of the project and the purpose and process of the 
witness seminar. Participants were then invited to introduce themselves and describe their first 
engagements with HIV. 
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Graham Hart: I’m a professor of sexual health and HIV research at University College 
London. I’m also Dean of the faculty of Population Health Sciences. I’m almost certainly Dean 
because I had a huge academic success because of AIDS, so I think that’s quite an important 
thing to say, that people’s careers and lives intertwine and I think that’s important to register 
really pretty early on. I started in 1986 at Middlesex Hospital Medical School as a lecturer, 
sitting in a clinic in James Pringle House which was on Charlotte Street where I met colleagues. 
Jane [Anderson] was there very early on.  So that’s where I come from. 
Jane Anderson: I’m a doctor. I qualified in 1984 and my first job at St Mary’s Hospital was 
on the AIDS ward, and my clinical career has really been in parallel with the epidemic and I 
spent time at James Pringle House in 1988 to 1990 so we overlapped. And again, I’ve had an 
extraordinary set of experiences during my career which have gone from no treatment to some 
treatment to good treatment, to where we are today. I’ve worked only in London, I haven’t had 
any experience outside a big city, I haven’t had experience outside the UK, so I’ve got a very 
particular experience.  The majority of my experience has been in East London, so seeing how 
the epidemic has affected really quite a diverse population.  I’ve also been involved in the NGO 
sector, and I’m currently chair of the National AIDS Trust, and I’ve got a variety of other 
charitable NGO trust roles. 
Jane Bruton: I’m a nurse. I retired four years ago but I’m still working now in Imperial College 
in London as a researcher. But I trained in nursing from ‘78 to ‘81, I worked in neuro medicine 
until I moved to Leicester and worked in general medicine. I’ve always been political, I was a 
political student and I was involved in the 70’s at a very political time, and particularly around 
gay liberation and women’s liberation etc. So when HIV, well, when AIDS first raised its head, 
then I wanted to work in it because I thought, you heard all these stories about how badly people 
had been treated, and a job came up in the infectious diseases ward in Leicester, which is where 
I was working at the time.  
So I’ve had a little bit of experience working outside of London, where we had very few 
patients, but I cut my teeth on that. Then for personal reasons we moved to London and I got a 
job initially at Chelsea and Westminster as a health advisor, and then the job that I really wanted 
which was a ward sister on Broderip ward at Middlesex Hospital which was the first ward that 
opened specifically as an HIV ward. That came up and I got that job, and I was there like Jane 
Anderson through that period. I was there for ten years. When the ward closed, because 
obviously with treatments we then saw all the major hospitals reducing from two wards to one, 
we moved to University College Hospital and linked up with tropical medicine. That move was 
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very difficult for me personally and professionally, and so I then went to Chelsea and 
Westminster for 14 years and worked as, well my job changed several times but mainly as a 
nursing development advisor, a senior nurse responsible for sexual health and HIV, so working 
on the ward in the outpatient clinic. And I guess a lot of my involvement in HIV has been about 
trying to develop a holistic approach to care.  From a nursing point of view we’d learnt so much 
in theory about what nursing should be, but I’d never really seen it in practice, except a couple 
of instances in Leicester where I was very fortunate to work with very progressive nurses, and 
so HIV just lent itself to us being able to really do what we thought nursing should be. And so 
that’s been really my career about trying to develop nurses, develop the role, and ensure that 
patients are treated as human beings and not patients in the context of a very difficult time.  
That’s me, and I’m a trustee of Positively UK, I’ve done lots of work with patient involvement 
at Chelsea, and I do a lot of teaching in Eastern Europe. I also did go to Uganda for three months 
when I did my masters in medical anthropology, particularly because of the African… at the 
Middlesex I felt disarmed really about how should we approach people who are coming from a 
very different culture, so medical anthropology really helped me to develop those skills really. 
So yes, I think that’s it. 
Emily Jay Nicholls: I’m the postdoctoral researcher for the UK component of this project. My 
PhD research had me following the making of an archive of the UK HIV/AIDS epidemic, and 
now I’m here working on EUROPACH. 
Simon Collins: I currently work at a project called HIV i-Base and my job involves tracking 
treatment and treatment advances, and trying to understand some of the science that’s going on, 
and try and report that in different ways. I do that in a technical bulletin for doctors that I’ve 
been editing for about 15 years. More importantly I translate it into non-technical, I say exactly 
the same information but in a very non-technical way, so that there are various patient resources 
I guess, and then i-Base also runs a direct service where people can ask about their treatment, 
you can email, you can ask questions online, you can phone up, and we’ll take you through 
different options. And all that has been from a background of peer advocacy, of involving HIV 
positive people directly in taking an active role in choices, and options of choices that have the 
biggest impact on their life. Historically this comes from a situation where medicine is a 
specialisation that you’re not really supposed to get too involved in, and clearly I think the 
opposite. All those boundaries and all that jargon, and all that background can get in the way 
of people just understanding an option between the blue pill and the red pill, or what that is, or 
if you need the pill at all.  
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And then my personal history is, I was born in 1961, so my 20’s, in my late teenage and 20’s 
years I was exploring and finding out that there was a world out there that was different to the 
world I’d grown up in politically and socially, definitely. So it was a great time of finding other 
people that were gay, finding gay life. Really important, I similarly became politically really 
active, got that shock that the world could work in a different way to the way you had expected 
it to work, and then just the solidarity that you get from working with other people. So 
politically I was active through all those horrendous Thatcher years which was just this 
dismantling of our country, dismantling the idea of society, and that period was incredibly 
fertile for just having coalitions and overlapping with people with all sorts of different issues, 
whether it was anti-apartheid issues, or whether it was housing advice or whether it was lesbian 
and gay issues and visibility, or women’s rights, all these things were tremendously vibrant. 
And without much effort you suddenly found yourself in a complete network of people who 
had another set of experiences, all sorts of different experiences.  
So I was quite involved politically there, bunch of left wing friends really involved in a little 
bit the minors’ strike and the print workers strike, and the lesbian and gay support groups for 
the seamen, things like that, and then Section 28, all that stuff that was going on there. We had 
marches on the local authority approaches to everything, to selling council houses, these are 
crazy things, so that the pockets of resistance tended to be urban left wing boroughs, and they 
were very dynamic. If you tell people now that Haringey Council had 3,000 people 
demonstrating outside the council meeting for lesbian and gay rights, and that councillors were 
throwing things across the room, and papers and cushions, and that’s been kept off… someone 
told me the other day they’ve got this on film. And so it was a very strange activity, and I was 
interested in doing that. And during that I remember HIV first being reported in Capital Gay, 
and it was sort of, it was really another world, but it was at the level that it was single figures, 
‘now there’s four cases’. I remember that, an inch, on the front page, I think – I hope – it was 
on the front page, or maybe it was inside, but I remember it going back that early, and then I 
found myself just socially in a group, and the UK is different to America where everybody was 
positive years before anybody knew anything. UK was very different, but I found myself in a 
social group where my friends were quite badly affected, assumed everyone was positive, that 
sort of network.  
And then bizarrely I dropped back from the political stuff, and my life became more around 
social setup and what you did on a day to day basis, and I always believed there would be 
treatment, I didn’t know about the vaccine, I have no scientific background by the way, I went 
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to art college, and my work involved in setting up a community art project where people had 
free printing, so I was doing all that sort of stuff, but I always believed there would be treatment. 
My partner back then always believed there would be treatment, and so life became a strategy 
to get from where you were at the time to still be around when the treatment came, and that 
almost didn’t happen. I was caught by 1996, my CD4 count was zero or had been zero for a 
while, or single figures, and so I was just caught by combination therapy with absolutely no 
expectation it would work. Really I had done DDI monotherapy and AZT monotherapy, I just 
stopped them because they didn’t make any effect on my CD4 count, and so I had that 
awareness. And at the same time there was a group of people in London who had been through 
the same experience, and there was an organisation called AIDS Treatment Project, and this 
random group of people who knew treatment worked were in this strange situation of saying 
things that the doctors didn’t agree with, and certainly the charities didn’t agree with. THT 
missed the boat and missed the boat on treatment, and all this sort of stuff, and so that projected 
me more into being active and interested in treatment. And since then I’ve developed projects 
along those lines, and met some amazing people and done some things that just weren’t part of 
my life’s plan. 
Matthew Hodson: I was 15 and decided it was about time I had gay sex, so I went to Heaven 
and I picked up this man who was 32 years old from New York, he was a photographer, and 
we went back to his hotel and we had the gay sex, and that was very nice, and then the following 
week I switched on the television, there was this documentary about this new virus which was 
affecting gay men particularly in New York, and people were dying, and I thought, “Well, that 
wasn’t a very good start to my gay sex life.” So yeah, so that was a bit of a panic. I went to 
university in ‘86, the iceberg and tombstone campaign came out shortly after that, and I was 
obviously… I felt I was more involved actually in the gay liberation stuff, I mean, Section 28 
was obviously a big part of those university years, and the activism that I was involved in.  
I came back to London, I joined OutRage! in fact I was a founder member of OutRage!. I did 
kiss ins and things like that and by the mid-90s I had been working at Gay Times and I realised 
when they came to World AIDS Day and they talked about the number of people who had died 
with HIV or people who were diagnosed with HIV, and I realised that I knew 4% of the UK 
total, and I thought, “That’s pretty heavy.” I started dating this guy who was the second biggest 
love of my life, and he was also American, and I knew right from the start that he was living 
with HIV, and I had to wait about a month and a half before he told me, and I was like, “Come 
on, just tell me I’ll be fine about it, it will be fine.” But it was very difficult for him, and of 
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course this was at the time when there were no treatments, no effective treatment, so we got 
engaged and my perception as I was in my 20’s was that I was going to marry this person and 
then he was going to die, and then I was going to be a widower at a very young age, and that 
was the deal that I accepted because I was in love.  
Of course, he rather annoyed me by then not dying, and in fact leaving me for someone else. 
So that was frustrating, I had picked out my outfit and everything, and that sent me spiralling 
off into a very dark place. And so when I was eventually diagnosed in 1998 I wasn’t actually 
sure how I had become infected because on the one hand I could have been infected by having 
condom sex for three years with this American guy, but who would have had a high viral load 
because this was in the pre-treatment era, or I could have been infected from some random hook 
up in that dark period of my life. I certainly wasn’t seeking the virus, but I was so depressed 
that to be honest I don’t know if I necessarily took the precautions that I should have taken the 
whole time, sometimes I did, sometimes I didn’t. That diagnosis changed the way I thought 
about my life, I had been working as an actor and I decided that was just too stressful an 
existence to combine with an HIV positive diagnosis. So I left that, I was working at the 
Museum of London, and then a job came up at GMFA, it was just an admin assistant role, it 
was providing admin support to the positive campaign group, and to the research group, it was 
booking rooms and taking minutes and stuff like that. I went there and I was really impressed 
by GMFA because in an early meeting I remember going to they said… they had some question 
which we were challenged by and the then CEO said, “Well what’s the best thing for gay men? 
And whatever the best thing for gay men is that’s what we do.” And I thought that’s absolutely 
the right attitude, and I thought it was a really great place to work.  
So then by a process of a kind hearts and coronets process I rose to the top as CEO, top position 
at GMFA, and then last year I was asked to become executive director of NAM, providers of 
Aidsmap. I think I’ve always been passionate about information, I think that’s been throughout 
my whole life, about information and communication. So to be given the opportunity to be 
involved in disseminating information, whether that’s for gay men and NAM for international 
audiences, and I’m really keen to use whatever power we have to really look at issues for trans 
people who have been so neglected in provision of information, provision of services. Also 
keen to ensure that no one is left behind when… you look at late diagnosis, particularly amongst 
African communities, perhaps particularly amongst African men. So it’s been a real passion for 
me and something that I’ve been really excited to be involved in. 
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Deborah Gold: I’m the chief executive of National AIDS Trust, and I’m professionally fairly 
new to working in HIV, it’s just coming up to the end of three years working in NAT, but my 
personal background with HIV is that I became very politically active as a student, leftie activist 
from the age of 16 in my student union in my further education college, and so that meant that 
I had the most lovely coming out ever when I was 17 at the national conference in the LGBT 
party, and what that meant was that I had a whole group of university age, mainly gay men, that 
looked out for me through my early teens and university, and that was in the very early 1990’s, 
so I missed being involved in all of the Section 28 stuff, but it was a part of your everyday life 
and very politicising.  
So I became very involved in women’s rights politics and LGBT politics all the way through 
university, and I also became very close friends with somebody who is still my best mate who 
had himself been very active in ACT UP in the early years and stuff. So I feel like that was 
woven in a little bit alongside an experience I imagine everyone has had in this room many 
more times than me, but I was fairly young and a friend died, and we had that very intense 
period of living in a hospital for four days watching that happen in the summer holiday between 
my first and second year at university. So it’s been something that’s been there through all of 
my politics, and then work wise I’ve worked in the LGBT sector from almost immediately from 
when I graduated on and off in different places, and so I’ve seen HIV alongside homelessness 
and how it affects things, at Stonewall Housing and alongside hate crime when I worked at 
Gallup, and so actually eventually working specifically in HIV and NAT has been a bit like 
coming home to something that’s been there all the way through my politics and career. 
Edwin J. Bernard: In my current work I’m the global coordinator of the HIV Justice 
Network which is a global network of activists who want to make sure that people living with 
HIV are treated equally under the criminal law, usually in the context of non-disclosure, 
exposure, transmission in the context of sexual transmission. But that’s only been something I 
have been doing for the last five years. But my personal history, I’ve been living with HIV for 
34 years, diagnosed 29 years ago, and I was born in ‘62 so acquired HIV in ‘83, my second 
year at university. I was studying film and literature, and at the time it was misdiagnosed as 
syphilis and glandular fever, one after the other, and it’s only in retrospect I realised the 
seroconversion illness symptoms when I was actually working at NAM in the 2000’s editing 
the treatments training manual and realising the list of symptoms of seroconversion were 
actually very similar to the symptoms I had back in 1983, so a retrospective realisation of when 
I acquired HIV.  
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But I guess in those 34 years you could basically say the first half was really a very personal 
battle with HIV. My work, I was mostly an entertainment journalist, a music journalist, and 
then TV and then film, including Hollywood, went to live in LA in the 90’s. But my earliest 
writing about HIV was actually in the context of pop music, so I remember the very first World 
AIDS Day which wasn’t in December, it was I think in April in 1986, I wrote a cover story for 
Record Mirror that had Jimmy Somerville on the cover asking why the pop world hadn’t yet 
engaged in fighting AIDS, of course they did, some of them did very soon after. And then my 
other I guess cultural claim to fame was the very first music, well it actually wasn’t the first 
music AIDS fund raiser, that was Dionne Warwick’s That’s What Friends Are For, who I 
interviewed, but it was Red Hot and Blue which was the Cole Porter tribute, and I volunteered 
my time as the person to write all the press and publicity notes for that. It was through Chrysalis 
Records and I spent some time with a number of the artists including Jimmy, and it was quite 
a few of them, Jody Watley, there was a few of them I went to America, interviewed her and 
wrote about that, and that was how I became aware of the cultural parts of responses, because 
Red Hot and Blue wasn’t just about music, there was actually an amazing TV special that had 
a lot of the arts, like Jenny Holzer, an amazing American artist response to HIV.  
So I came into the cultural part. Then I moved in ‘91 to LA to become a Hollywood journalist, 
but also because I wanted to move to the light as it were. It was a very dark time living with 
HIV in the UK, not only were there no treatments, everybody was dying, and there was not a 
lot of hope, and so I made – it felt like a very selfish decision – I left my… I was with a partner, 
we had a house, I left all of that behind and went to live in LA. And I also wanted to go to where 
there was this idea of hope, and a lot of it was charlatanism I would say now, but at the time 
Louise Hay and her hay rides, the recently deceased Louise Hay, I went to those hay rides, and 
it was a quasi-religious experience being there and seeing people who were really on their last 
legs. So many people with visible KS and extremely thin, feeling like they had some kind of 
hope, including a number of my friends, some of whom believed in that and some of whom just 
thought it was bullshit and they all died anyway, and somehow I survived. Then also culturally, 
I was there when Philadelphia was released, I was there at the junket, I was writing about that, 
but it was interesting I never felt I could disclose that I had HIV in that world, but it was an 
interesting thing to write about HIV from a cultural perspective.  
Then I nearly died, moved to Vancouver, was there for the AIDS conference in 96, but had 
already become resistant to all the Protease Inhibitors, so it was an amazing experience to be 
there, but not actually… knowing I wasn’t benefitting myself. Took until 2001 to become 
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undetectable, and that’s when I became… when I moved my journalism from entertainment to 
HIV. Left a relationship, very… the opposite of Matthew’s experience, so I left the partner that 
expected me to die, and he was in Vancouver, I moved back to the UK, got a job at NAM, 
became editor of AIDS Treatment Update (ATU), I don’t quite know how that happened. It was 
a bit kind hearts and coronets as well there. And even then I was a journalist, I didn’t think of 
myself as an activist at all, and it was only really when we had the first prosecution for reckless 
transmission in 2003, and that was the first month I had become editor of ATU, and I realised 
there’s more about living with HIV than just surviving or taking treatments, of course it’s really 
important, there’s this whole other stuff going on. And then I became much more of an activist 
particularly around this issue of responsibility for prevention and transmission, and that led to 
my work now. 
Marsha Rosengarten: I never really know what bits to select in these things. So anyway I’ll 
try to say what I think might be most relevant to this meeting. I’m Marsha Rosengarten, and in 
fact my initial introduction to working in the HIV field was in Australia, and really my 
knowledge of the history of the epidemic is very Australian centric, and I think the sort of 
political context in Australia was very different to what it was here. The beginning of the 
epidemic was in a way a rare moment in Australian politics, there was a lot of support and I 
think that has affected how HIV as a policy consideration is now situated in Australia and the 
way medical care happens and so on. But I worked initially on a study that was to investigate 
whether and if so how the introduction antiretroviral drugs, this was around 1999, whether the 
drugs were responsible for the decline in condom use. What became apparent in that study was 
that it seemed to me, and working with a very close colleague Kane Race and also Sue Kippax 
(who some of you will know), that positive men were really quite inventive about how to 
negotiate sex without condoms, having faced the prospect of a life of always using condoms 
and now drugs had shifted that demand. But, by contrast, many HIV negative men were not 
situated in a way that would enable them to talk about why they were having unprotected sex. 
It seemed from what they said in interviews that unprotected anal intercourse was a real no-no, 
it was to, ‘put yourself at risk.’ I left Australia and moved to the UK for personal reasons, and 
worked with Graham Hart and Paul Flowers on a project where I became very interested in how 
the clinic was changing because of the introduction of antiretroviral treatments, and I met a 
number of people in the field then, like Jane Anderson, and Simon Collins who I don’t think 
remembers me knocking on his door a few times… 
Simon: I do, when I was at ATP. 
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Marsha: And much later I also met Edwin. I am now a Professor of Sociology at Goldsmiths 
which is part of the University of London, and much of my work is teaching and administrative 
work as part of a conventional academic role. My interest in PrEP came about in the late 90’s, 
actually it’s maybe 2004 I think or 2005 when the controversy about PrEP trials in Cameroon 
and Cambodia came out. I don’t know why I became interested in PrEP. I don’t find randomised 
control trials at all interesting, I don’t think I have a particular feeling for PrEP either, I certainly 
don’t live in a situation where I would require PrEP, my life is really pretty boring. But I found 
myself following the development of PrEP and the controversy and then the establishment of 
the big trials mainly in Africa but also Asia. I put a lot of effort into getting to know Bob Grant 
who led the iPrEx study. And one of the things that I was intrigued by was how those trials with 
MSM and with heterosexual couples were very successful, but with women the trials were not 
successful and the onus seemed to be on the women. They basically didn’t take the pills and 
lied, and so I wondered what we can learn from our research participants when they are 
recalcitrant.  
So I think this connects with what some people have said about the ways of knowing the field 
differently to that of the scientific knowledge, even though the scientific knowledge in the HIV 
field has been major. And from there I have become interested in other infectious diseases like 
Ebola, TB, and Zika which I think is particularly interesting because of the onus placed on the 
affected individual, the responsibilising of the individual and the absence of any medical 
intervention, just, “Don’t get pregnant,” or “Have an abortion,” when you live in a country 
where abortion is not legal. Lately I’ve also become interested in malaria through a strange set 
of circumstances. But I remain now, I suppose my main connection with the HIV field is PrEP, 
and how to think about PrEP in a way that doesn’t responsibilise the individuals that it’s targeted 
for. Although I do think that there is a very strong culture of responsibility in the gay field, 
because I think historically that’s how prevention happened.  
So I think there’s something very interesting about the way that people understand 
responsibility and engage with it in order to sustain a sexual culture in the presence of a virus, 
and I think Graham, when you said that careers have been built on the basis of this virus, I think 
it is an extraordinary field, and I don’t think that other fields know how much can be learnt 
from this field as a consequence of the history of it. But nor do I think that the field has really 
plundered what it can learn from itself either, so that’s how I’m here. 
Ingrid Young: No pressure to be the last one [laughter]. I’m not entirely sure why I have been 
invited to this but I’m pretty pleased to be here. I’ve come to this relatively new, I have been 
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working in research on HIV in the UK for about ten years or so now. Before that I suppose my 
first experience with HIV was, or my first memory even, was a friend had taken me to see a 
musical, I grew up in Canada, we went to Toronto and saw a musical in Toronto. At the end of 
the musical they had, this was in 1990, they had requested at the end, the Actors Guild Fund 
had been depleted through people accessing it because they were living with AIDS at that time, 
and they were asking the audience for contributions, and my friend’s father grumbled horrible 
things about how, “They don’t deserve it.” Horribly homophobic stuff, and I had no idea what 
he was talking about, I had no idea what they were talking about, and I think for me that was 
quite significant.  
So my engagement with HIV has always been through a rights based approach, so recognising 
not just the experience of people living with and dying from HIV and AIDS but also having to 
fight those really horrible responses to HIV and AIDS, and to LGBT communities. So I said 
I’ve been working on HIV in the UK for about ten years, I have never worked in London, my 
research was in Newcastle and more recently has been in Scotland, and what struck me has 
been, I’m really interested in the narratives of HIV and histories of HIV, and the histories that 
people tell, and I think they’re really important, and I’ve been really lucky to be able to hear 
and listen to it and share some of those histories through my work. And what struck me in the 
work in Newcastle and similarly in Scotland has been the role that the memory of the early 
experiences of HIV and activism within that and living and fighting within that early period 
have continued to play a role in experiences of HIV and stories of HIV as we go through into 
the 90’s and 2000’s and now.  
And as I came to HIV here about ten years ago, at the beginning of the treatment as prevention, 
so not the treatment era, I suppose people recovering, but also the treatment as prevention. So 
it’s been an interesting point to enter and to work with communities actually to think about how 
do we think HIV in the light of a long history and a particular history fighting for rights and 
fighting for treatment, when treatment now means something entirely different, or perhaps 
doesn’t mean something entirely different but is situated scientifically as something different. 
And again, I’ve been really lucky to be able to work with community organisations throughout 
my research and to learn a lot from them. Most recently I have been working with HIV literacy 
but I suppose not just how do you understand how to take PrEP, so Simon your point about you 
just need to learn what pills to take, but also I’m interested in the broader conversations about 
how communities facilitate those discussions and those conversations, so how communities can 
take in the new scientific knowledge and make it their own and employ it in ways that are 
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appropriate for them, and how communities can teach clinicians and work with clinicians to 
shape health experiences and access to treatment, and access to other things that are necessary 
to live well with HIV in the current period.  
Marsha: Well there’s a wealth of experience here, and I am in two minds about whether to ask 
you to think about the present and how we’ve come to this or go back to the beginning, because 
you have all spoken about that, but I think maybe it might be good to talk about the first 
recognition of AIDS in the UK and what you recall happening around that from the political 
context to the situation. Jane you mentioned, and I don’t know whether this is significant at all 
but you mentioned that there were two wards in major hospitals and one closed, and I was 
wondering what were the two wards and why did one close? 
Jane B: At Chelsea and Westminster, the Middlesex Hospital, the Royal Free I think, and St 
Mary’s, there were two HIV wards, because when I first went to the Middlesex Hospital there 
was just Broderip, but they had already been planning at that point, so that was in 89, that we 
needed another ward, because of the numbers of people coming through. But obviously once 
antiretrovirals came in, then we needed to shrink, and the same with Chelsea and Westminster, 
so they had two wards, one of those wards shut. Actually, it was an amazing time to think that’s 
what was possible, but of course it was also a very difficult time for the nursing staff, because 
we were losing our jobs, but also you had known which patient had been in which bed, and 
memories are also about the environment and the bricks and mortar that are there. Also for the 
patients, it was very difficult for people who were coming in constantly to suddenly realise that 
they won’t be coming into Broderip anymore because it was going to shut and it was the Charles 
Bell ward that they would be going to instead. And the same with Chelsea and Westminster, 
that they shut. And I’m aware of that because I went on to work there, and the wards had slightly 
different cultures, the way we nurse was slightly different, patients preferred one ward or the 
other, and so that was a strange time, because it was obviously a huge step forward because of 
the advent of treatment and that meant that people weren’t coming in sick as they were. But of 
course it was also a time of sorrow and loss for the people who had been working there, and for 
the patients to a certain extent. 
Graham: But that was much later wasn’t it? Very early on there was quite a lot of denial around 
HIV. It seemed to be very American, lots of numbers there, although a number of activists, 
particularly through THT and other organisations started responding to it in the UK. I remember 
being on Gay Switchboard in Manchester in ‘83/84 just doing a routine evening answering the 
phone, and somebody rang up and was asking me about AIDS, and I said, “Oh yeah you’re 
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more likely to be hit by a bus than you are to get AIDS.” And I was in complete total denial 
because it was over there, relatively few numbers, and it seemed very distant. So I can’t have 
been on my own in that experience of denial, obviously very rapidly I changed my perspective. 
But not everyone was immediately out on the streets fighting this, it was really frightening, and 
denial seemed like a good response actually.  
So I think by 1990 I was in a clinic where people could barely walk up those steps into James 
Pringle House because they were so ill. But by then it was also extremely exciting 
professionally, because suddenly you had a set of skills that people were interested in. I could 
actually talk to the men. The first study I was involved in they were going to interview men in 
clinics, I said, “Well why don’t you go to bars and clubs?” And the response to that suggestion 
was like, “What?” And so that was my innovation, going out into communities and asking 
people about this. We couldn’t have done needle exchange if it hadn’t been for HIV, we opened 
the first needle exchange for injecting drug users, but because of a political environment in 
which even though we had a Tory government, Norman Fowler just said, “Yes.” So again, that 
doesn’t sound like a… it’s not an activist thing to say how marvellous a Tory government was, 
but in fact it was immediately responsive through Norman Fowler to our request for DoH 
funding for the needle exchange, which allowed us to demonstrate that needle exchange was 
safe, it was a means of prevention.  
So there are several histories here going on, and colleagues were activists as well, weren’t they? 
So I remember in the clinic there was a huge debate, a lot of doctors didn’t want to provide 
condoms to gay men because, “If you provide condoms to gay men you’re going to encourage 
them to have anal sex, so you shouldn’t provide condoms.” So, some people from THT came, 
and said, more or less, “This is mad,’ and there was a big debate in the clinic between the 
doctors who were in favour and the doctors who weren’t on providing condoms for gay men, 
and this sounds like dinosaur times, but this was very urgent and meaningful and the politics 
were in the clinic as much as they were in… 
Simon: The same old tired arguments all appeared over PrEP, and they appeared at a regulatory 
level. The reason PrEP took four years to be approved in Europe was because the EMA said, 
“But we’re a bit worried about what will happen if we do this.’ That’s a regulatory level, there’s 
nobody decides whether a statin should be approved depending on whether you’re going to 
change your diet and eat more healthily, it’s outrageous, and that is rooted in social inequalities 
that still find their way through the systems that make decisions about people’s lives. 
Witness Seminar: Antiretroviral Drugs 
Nicholls and Rosengarten (eds.) 
22 
Deborah: And you saw that in the press release from NHS England in the UK as well and in 
their attitude, that same kind of thing. 
Matthew: Yes, this is a lifestyle drug rather than actually… and people who take it are 
irresponsible rather than admitting that people who take it are actually taking responsibility for 
their own health. 
Graham: Resources will be taken from children with rare disease or arthritis or whatever. The 
idea that you then take money from other people and put it into this is not quite the way it 
works. 
Deborah: And the argument that PrEP might in some way make people stop using condoms, 
and the logical extension of that is, if there was a cure would you not let people have that in 
case it encouraged people not to worry about…? There are few other diseases that I can think 
of where there’s that level of…  
Jane A: We had the same discourse around the pill in the 60’s, “If you give women the pill and 
they won’t use condoms then goodness knows what will happen then,” or women will have sex 
for pleasure, goodness me, heavens. So the same discourse was fought by women in the late 
60’s and it’s come round and some of those arguments are just coming back round again. But I 
was just reflecting on what you said, I think this ties in because my first experience was in the 
ward, an infectious diseases ward that was full, it wasn’t a designated ward, it was the infectious 
diseases ward at St Mary’s and it was full of young men dying, and my next job was at 
Middlesex where there was a designated ward and the next job that I had was to go and make 
a ward like Broderip and Charles Bell at Barts. I got there in 1990, armed with having seen and 
worked in those areas, and I remember a question from a very senior colleague at Barts who 
said, “Oh my dear do we do that here?”  I said, “Yeah we do.”  “Oh I didn’t think we did that 
at Barts.” So this is now ten years in and I suppose, coloured by having seen and worked at the 
places I’ve worked, “Well of course we do it here, and we’ve been doing it really well,” so I 
got enthused. But the idea that then leaping forward 20 year to whenever it was, 2014/15, having 
been in that medical environment, to then be in a position where there is a tablet that you can 
take that stops it, it was unbelievably exciting, and the idea that anybody of my generation 
would not want that like now and quickly. I think we’ve seen things that have just, they have 
been so powerful, that the idea that you would not want to do something and have it available 
straight away, I still can’t understand how we can be in that position. And your point about 
regulation and politics is absolutely right, it’s shocking. 
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Simon: It would have been in the beer kegs at the Market Tavern really, if PrEP was available 
in the 80’s. I’m not saying pills are the answer to everything, but really, if you get sick you 
want a way of curing it. I remember James Pringle House, I remember Thomas Macaulay and 
Elizabeth Gaskell ward, and the support that came from health professionals on the whole. If 
you were coming at it from someone who was positive, you just offloaded a lot of your 
responsibility and your trust in your doctor helping you. The doctors and nurses, care and their 
roles as activists is absolutely right on. You couldn’t be involved in this unless you had some 
sort of activist level.  
But the brief1 starts at 1996, and I was a bit worried about that because there’s so much that 
happened before then. If you go back to individual experiences about when you first heard, if 
you first heard in the early 80’s when it was first discovered, when this thing was discovered, 
it was very science fiction. It’s exactly what you’re looking at in films and in movies, and all 
this sort of stuff on there, and because it’s inexplicable and it’s completely out of the blue, and 
there was no way of making sense of it. So you would get a crystal and you would go to some 
crazy Cass Mann thing and you would do the whole lot of things that you would in the absence 
of even viral load, you couldn’t prove there was a virus. There was all that nonsense that was 
going on about the virus, and then the overlap with such a slow access to treatment, for it to 
take six/seven years to have your first drug and that drug was so… I remember running around 
to the newsagents to get newspapers when you heard about… this is all before an easy way of 
getting information, I ran round and got the newspapers, and I heard about AZT.  
And America – unless you had some money or you were very resourceful, I didn’t go to New 
York, I couldn’t get the air fare together. The only way most of my friends got the air fare 
together is they did that, was it a Hoover commercial, or a washing machine commercial? It 
was a big giveaway of tickets, and that’s how most people got there. But the people who were 
affected in the UK really early on were connected to that network. You were broadly, there was 
a set of gay men who were pretty well off, pretty sorted out, they were pretty, basically if you’re 
in the leather set really, into that, then there was the international network which was Berlin, 
Amsterdam, San Francisco, New York, maybe LA, maybe a few other places as well and if you 
overlapped in that then you were clearly at a high risk. So there was a little bit of that in the UK 
and some of my friends were involved there or connected through there. But that didn’t overlap 
at all with my politics, their politics were horrendous most of the time, and so I had disconnects, 
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where you fit in with different places. But the idea of steps going up to a clinic, this was in 
terms of whether there’s access to somewhere, and the association with places is really 
important. There were times when I couldn’t even go in that area where the hospital was, 
because of experiences there, and then there were also places where I kept having my care 
where my partner died, and that’s a tough thing to do.  
Marsha: Actually it is pre-1996, not from 1996, and I think it is interesting… 
Simon: So the activity before then was huge amounts of community activity and it was really 
about fundraising, and then entrusting people. A lot of British charities are based on doing 
things for people, and luckily there were people there that made sure if you were sick or if you 
were positive you could get benefits. The US experience is completely different to that, you 
actually had people who were on the streets and you weren’t admitted to hospitals because 
10,000 people were positive in New York when they first had the test. 
Jane B: I was just going to pick up on Graham using the word innovative, and I think that’s 
really important to capture about those times – and now, really – because as a ward sister I was 
just left to get on with it. Nobody really wanted to have anything to do with the ward, 
particularly at a senior management level. So we could do things that had never been done 
before really, and that was what was so exciting. 
Graham: But it was individuals as well, people like you and [Clinician 1], [Clinician 2] they 
pushed ahead. [Clinician 1] couldn’t originally go into the consultant’s dining room because 
they wouldn’t speak to a junior physician, so this was before, because it was just too low a 
specialty.   
Jane B: And [Clinician 2] was so important in that. 
Graham: So [Clinician 1] persuading [Clinician 2] to come on board allowed the thing to go 
forward, so you had to make allies of people who were much more senior so that you could get 
things done. But it’s funny how that individual action so to speak has these massive 
consequences. 
Jane B: Yes, and people being prepared to take risks. 
Graham: Which as a sociologist, I trained as a sociologist, you never think in terms of that 
kind of leadership and innovation and direction, but it’s absolutely critical to getting things 
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done in the same way, as activists obviously get it immediately. But when you’re in an 
organisation… 
Simon: But Jonathan Weber said things didn’t really change in the UK until you had the 
Horizon programme. You had to make those links in terms of the social response. Lots of things 
went under the radar until then, and actually the response afterwards wasn’t entirely positive 
because the 80’s, if you actually pull out some of those ways that HIV was reported, or anything 
was reported, this is a very hostile climate to have been living in, and the healthcare services 
were these little islands of calm and when you went into the wards. Even something as simple 
as having a kettle or a fridge or a toaster, or the ability… hospital food has never been great 
really at the best of times that you had, you changed approach to healthcare for all sorts of other 
areas.  I’m not sure holding on to the smoking room [laughter]… because basically it’s a quality 
of life thing that was going on there. So you made sure people had TVs and videos and stuff to 
do, and all that stuff which in terms of receiving care, you were being given kindness at a time 
when outside it was incredibly hostile.  
And actually some of the hostility ran through places where you wouldn’t have expected it. 
There was a lot of division because of fear in most gay clubs if somebody was positive, there 
was discrimination and hostility and then there was another set of discrimination depending on 
whether you were actually sick or not. So there was this whole protective thing, “But my CD4 
count is okay so this is going to be okay.” And having learnt the science afterwards, the stuff 
we didn’t know back then, all the world’s experts, the bit that keeps me interested in science is 
when experts get it completely wrong. Through the whole of the first ten years Fauci and all 
the top scientists believed that actually this was a latent stage of infection and then what on 
earth could be the trigger? At some point you have this infection and then there’s latency, and 
something as simple as a viral load which just happened to be developed in the 80’s, shows that 
actually it’s a slowly progressive illness and this is something else that’s going on. And so it’s 
interesting, incredibly interesting, and incredibly conflicting in terms of the emotions as well. 
Jane A: I think the thing about the support and the end of the wire thing is really important 
because the support I found as a clinician came from really unexpected places, and so I had 
exactly some of those experiences about colleagues going, “Oh, I don’t think we do that,” and 
then some of the most unexpected colleagues at Barts absolutely being committed. I remember 
a very senior surgeon, incredibly stiff pinstripe suit, with a man who needed to have a 
splenectomy and he got a platelet count of two, it was blood absolutely all over the place, and 
I remember talking to the surgeon, Barts surgeon, pinstripe suit, and he said, “Of course he 
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needs an operation, I’ll do it tomorrow. What do you mean bottom of the list? Of course not.” 
And suddenly I realised that there were real allies in some really unexpected places, and the 
professor of medicine at Barts, the most terrifying man said, “Of course, yes, what do you 
need?” And suddenly there were people really supporting, and the thing also I remember very 
clearly from starting at Barts is that I didn’t have a proper office, I didn’t have space, I didn’t 
have a place to see patients, and somebody who was part of ACT UP came in and he said, “You 
can’t work like this.”  [Laughter] and he said, “Well who should I complain to?”  [Laughter] 
and he said, “Well I don’t think this is adequate, and I think we could do something about this, 
let’s say six weeks shall we and see whether you’ve got the proper facilities by then, and if not 
well we could bring some chaps in,” because there were all the people doing chainings, and he 
said, “We can bring some guys down and do a chaining for you.”  [Laughter] six weeks earlier 
I had got people, “Oh do we do that here my dear?” So I said, “Look can we just put a hold on 
the chaining?”  But nonetheless the very fact that one of the people who I was there to care for 
cared for me back to that extent was transformative, and I thought okay between us… and we 
got an office, and we didn’t do the chaining. But again the unexpectedness of some of those 
things was fabulously important. 
Graham: But another time you might want to look at other diseases and the relation to HIV, 
because I couldn’t understand later on why there was such a focus on PPI, public patient 
involvement, because that’s what you had to do. You could not do things to gay men, they were 
very articulate and often coming from quite powerful backgrounds themselves, they weren’t 
going to take this stuff, and so you just had to engage otherwise there was no permission to do 
the work, and certainly for research you absolutely had to engage. And I did the same with drug 
users, because you couldn’t progress without them, and so then PPI comes 20 years later and 
it’s really bizarre, and you look at cancer services probably now still, and none of the learning 
or it’s just coming through now, the learning from what HIV did, but that’s another story, but 
what we take for granted elsewhere is just not the same. 
Marsha: There are a couple of things about Ebola that resonate there, that Ebola relapse is 
thought of as if the virus stops dead for a number of years and then just re-emerges, and when 
I’m reading it, I’m thinking, “Have they read about the history of HIV?”   
Graham: And sexual transmission as well. 
Marsha: Well sexual transmission yes that was definitely not considered, but also about 
working with communities rather than actually isolating them to the point that they had no 
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resources for everyday life. I think there is something really extraordinary about the dynamics 
of the HIV field, but I was wondering when you said earlier about how Norman Fowler agreed 
to needle exchange and so on, what was it, because much of what’s also been said is this 
incredible sexual moralism that purveyed the epidemic and who is responsible, and the 
stigmatising and so on, and yet it seems that this figure in a Conservative government made an 
enormous difference in terms of responding to the initiative of you and other people. 
Jane A: He made it a health issue and there’s that amazing quote when I come… there’s 
something in parliament when he was asked some difficult question, it’s the guy from 
Manchester, Anderton2 the chief constable, and Norman Fowler sat up and he said, “We do not 
have the time for moral discussion, this is a health problem, this is a health emergency, we do 
not have time for any moral debates, we’ve got to do something about it.” And I just hold that 
as a quote thinking okay yes, and for us as health professionals hearing this is it’s a bit like 
alcohol dependency and drug use now, is it a criminal social issue or is it somebody who is ill? 
Graham: But he was quite clever in a sense, using health politically. So if it’s health it’s 
permissive and you have to deal with this. But of course, health is absolutely morally bound up 
with a whole set of ideas as we’ve just been talking about, in terms of regulation for example. 
But it’s a nice short hand that is for the moment permissive because if it’s cast as a health 
problem then maybe unusual things have to happen for it to be addressed. But it was politically 
astute to cast it in those terms given the moral mess that we were surrounded by in terms of the 
views of government generally and Thatcher in particular. 
Jane B: And he had a big battle within the Tory government, Thatcher and Willie Whitelaw 
etc, all trying to stop some of the initiatives. But that’s where he had that link with clinicians as 
well and activists that I think made a bit of a difference in terms of what he was able to get 
through. 
Graham: And he was highly regulated. The needle exchange wasn’t just opened up, it was 
very strict about where you could be, what you could do. At one point it was the number of 
needles and syringes you could hand out, it wasn’t a free for all. But again, I went to a 
conference in Sweden and they were completely opposed to needle exchange because they were 
so concerned about the impact on drug use, and again a moral conceptualisation that if you 
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facilitate it, it will just go crazy and there will be many more drug users. And I was, by talking 
about this, and because I again used HIV as the excuse because actually if you provide clean 
needles you don’t get Hep C, you don’t get abscesses, there are other kinds of positive sequelae 
from this, and I was trying to think in a more holistic way. But that was just not considered to 
be an acceptable way of thinking, and I was really shouted down at a conference about 
introducing this, I was immoral for facilitating drug use, and that was from health people. So 
there are debates within, it’s not hegemonic, it’s completely fractured and fragmented like any 
other area, it has those elements. 
Simon: I think it’s nice that there was a success that came with needle exchange, but I’m really 
uncomfortable with trying to rewrite that as a positive HIV response from government because 
government did absolutely nothing for gay men, it was all done by community activity, 
fundraising, health information, the Kobler Centre was set up by charity awards, by charity 
fundraising, and actually you had a government response, and Norman Fowler is uncomfortable 
about it now because every time he speaks he has to muddy up the water about, “Oh it’s lovely 
we’ve got gay marriage,” actually that was a government that was absolutely hostile and is 
directly responsible for the reason so many gay men are now HIV positive to say you cannot 
talk about sex in schools. And there was a raft of gay teachers who were immediately put in a 
really terrible situation and health education, we come from a constricted sex negative culture 
and that was used to make people feel, to twist the knife when people are particularly 
vulnerable, these governments, the government’s response back then was shocking. 
Graham: I agree absolutely, and the reason that Fowler put it through was, you’re absolutely 
right in terms of gay sex and so on, it was because they feared a heterosexual epidemic, and so 
what they were doing they were doing this in support of preventing that, because of course it 
didn’t. Not that it didn’t matter about gay men, but they were not so very bothered in the way 
that you’re rightly saying. They did it because they thought it was the bridging idea that 
injecting drug users would have sex with innocent heterosexual people and they would be 
infected, so bring in needle exchange and that will stop. 
Simon: But it was a crazy response to put a leaflet in every house, it was a scaring teenagers 
from having sex response, and that knocked through directly onto prejudice and stigma against 
HIV positive people, and to gay people, and to anybody else who got caught in that net. It was 
a shocking response, it wasn’t a good strategy, and it didn’t come with the resources for the 
people that really needed it. It ticked a box for a leaflet and it was a scare campaign and I don’t 
think that it should be rewritten without a balance there from response. 
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Jane A: The same thing then has happened again. And going back to TasP and PrEP, because 
the history of how to treat everybody in this country was also very flawed and government 
didn’t want to treat everybody, and we had to fight extremely hard to make sure that people 
who didn’t have the right citizenship were able to access to care that they needed, and we made 
arguments for many years about human rights and that migrants had human rights and should 
be treated, and that it was about decent medical care. We got nowhere at all until TasP, and it 
became clear that people who were treated were not infectious, and then the discourse became, 
“Oh, actually, it would keep the population at large safe if migrants got treated,” and it went 
through. But it was exactly the same discourse, but 20 years later. 
Simon: That is absolutely remarkable that this country provides HIV care irrespective of 
residency status. 
Jane A: But we had to get it because it was that thing that we needed to happen. 
Simon: It’s an example of how policy people working behind the systems with the way things 
work can have remarkable effects without any level of grass roots activism. You get this 
amazing response because a few people pick it as a target and decided, “We’re going to go for 
this,” and then you get this amazing response which is remarkable, but it happens without 
people having to necessarily have been so involved, so it makes you vulnerable as policy 
organisations or as activists behind the scenes, because it doesn’t necessarily come from a grass 
roots perspective. You definitely need both, you need people working on every front doing 
everything you can, wherever you can, and luckily we move forward a bit. But the history of 
treatment as prevention it’s just cracking that through now, it’s cracking it through, and yet 
you’ve got US guidelines 20 years ago were suggesting that would be a reason to start treatment 
earlier to protect your partners. 
Jane A: And we had to fight for NHS England, that had to go through and we got that through 
whenever it was, and we still don’t have universal commissioned treatment for everybody, it’s 
free for everybody, but the commission… 
Simon: It’s commissioned at CD4 350. 
Jane A: We’ve still got that in the service specification in this country so that’s still waiting to 
be dealt with. 
Marsha: What does commissioning relate to? 
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Jane A: So what’s happened is in 2012 the Lansley reforms went through, 2013 when they 
went live, HIV specialist treatment and care sits under the control of budgetary control of NHS 
England, a new statutory authority separate from the Department of Health, and they are 
holding the budget, and whenever you want to do something new or different a full application 
process has to be made to the top, that’s when PrEP got sucked into that.  
But the TasP piece we got the data, we had all of the information and Simon was on that writing, 
you helped write that I think Simon, you were there for the TasP writing piece. But the whole 
thing had to be written out with every bit justified, and then it goes to a committee, and it took 
a year even after getting the first thing written before it was considered and actually it was 
funded. There’s lots and lots of good scientific data that starting treatment early is very good 
for everybody in many ways, and yet that has not yet gone to NHS England commissioning 
board, I think it’s going in the next month or two, but the policies have been written, and so in 
this country NHS England pays for treatment for everyone with a CD4 count of 350 or below, 
the national guidelines say everybody should be able to access treatment, international 
guidelines say the same, but our funders don’t yet pay for that. 
Ingrid: In Scotland it’s different, but I think this is an interesting division and policy. 
Simon: The workaround is that doctors take no notice of that. 
Jane A: We do it anyway. 
Simon: And there’s a cover that if you are concerned about transmission then you can access 
treatment earlier. But the reason they start at a higher CD4 count is there’s clinical evidence. I 
love randomised clinical trials because it shows that everybody benefits from treatment even at 
high CD4 counts, and that big study that looked at whether you start at 500 or below in the UK. 
When that study was being planned the feedback from doctors was that nobody will ever start 
treatment at 500, you can’t have that in a randomisation, we might get away with 450, but you 
could never do that. Now it’s completely changed, and the first response to treatment on the 
one hand is you’ve had these remarkable responses, Kaposi’s Sarcoma (KS) disappeared. I had 
friends whose faces were covered with KS, and it just edged all back and melted away, and so 
the activists then who knew treatment worked then had to… the phone line we set up, all that 
people wanted to know was, “Does treatment work?” And it was coming from the fear of side 
effects. And so you could have 20 people who did a few nights a week, and we had pizza and 
the phones would ring, and people would just ask, “But do they work?” And the fact that you 
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were there and taking the meds you could say, “Yes, they’re not perfect, you might need to 
balance them with this, to balance this side effect or manage this, or switch round,” it was so 
important that we can’t miss in the time we’re talking here. And then the next thing that 
happened was the fact that those drugs weren’t all so good.  
So two issues I would like us to talk a bit about is how we felt when treatment arrived and then 
how we managed the fact that it wasn’t perfect. So actually, even though you had this treatment 
the consensus for the first ten years, more than ten years, at least through to 2005 was that you 
would wait until as long as possible before you needed treatment, and yet now you’ve got 
clinical evidence that shows that’s not a good thing. It’s not all the CD4 count, it’s the ongoing 
viral load going on in the background that is much more serious than people realised. So I would 
be interested to hear, Edwin, how did you feel, because you must have been that situation of 
having… because I remember we had the Delavirdine discussion, you were the only person in 
the UK who was using it [laughs].  
Edwin: Well, I was in Canada 
Simon: But that point of did you recognise that you… because the whole need to understand 
about resistance was a new field, brand new field, well HIV was a new field, if you asked people 
who were scientists what immunology was in 1981 it was two big textbooks, and now it fills 
libraries. 
Edwin: Resistance wasn’t on the agenda. So I was in the saquinavir registration study, taking 
saquinavir, DDC, and I took delavirdine, I did all kinds of all the monotherapy, dual therapy… 
Simon: Saquinavir and DDC, you poor thing. 
Edwin: …everything… and actually I went into the saquinavir registration study because I 
knew they were doing viral load tests, and this was ‘95, I was living in San Francisco at the 
time, and I was expecting to get my viral load, it was like, viral load? It was amazing, at the 
time, that you got to know your viral load, and I was so disappointed to discover that the drugs 
were like… Okay, I was ambivalent about the drugs because my own history with them was 
that, just like you were Simon, I took AZT and DDI and they didn’t even work for me, just had 
lots of side effects. But I wanted my viral load, and then they were like, “Well actually we 
won’t give you the viral load until we have finished the study, because it’s double blind placebo 
controlled.” So after that I sent the pills off to a lab, and there was… I can’t remember, it must 
have been AIDS Treatment News I think, there was a little mail order ad, you could send off 
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your drugs to be tested to find out if it was placebo and it came back and it said this is protease 
inhibitor. I was so excited [laughter] I unblinded the trial! But when I left the trial, when I 
moved to Vancouver in ‘96, because I wasn’t feeling any better, and then they gave me the 
results and it turned out of course that I had acquired resistance to saquinavir within three 
weeks, and that I had a viral load that it had maybe I think gone from 300,000 to 50,000 and 
then back up again. So that was a waste of time.  
But my own personal experience with treatment was incredibly ambivalent for a really long 
time, because it was all about toxicity. You talked about Cass Mann, I remember going to Cass’ 
workshops. You talked about denial earlier on and that’s how I experienced my HIV, I didn’t 
take a test until ‘88, I didn’t start using condoms until ‘86, it was just, “Avoid Americans’. I 
didn’t know I had HIV in ‘86, and I just avoided Americans until someone said, “You really 
should use condoms with me because you don’t… I don’t know if you’ve got HIV.” And I felt 
dirty when he suggested it, but he was right of course because who knows how many people I 
may have exposed to HIV unknowingly during the time I was undiagnosed and wasn’t 
practising safer sex. But the treatment stuff was just, it was all “Poison.” It was like, we weren’t 
particularly excited as individuals about AZT, or in fact any of the early monotherapy, even in 
’96. So I was there at the Vancouver conference, and everyone talks about this as the amazing 
moment, but not only did I not benefit personally, but so many of my friends continued to die. 
It wasn’t like ‘96 and everything got better, there were many people who didn’t benefit from 
the early PIs, and those early PIs were not great, they were particularly… full strength ritonavir 
for goodness sake.  
So for me, and I think for a lot of people it was Kaletra, it was the second generation of PIs that 
certainly made the difference for me, once they discovered that low dose ritonavir could boost 
PIs, and that made the difference, and that really overcame the resistance. So when I moved 
from Vancouver to Brighton, although interesting side note, because I was living in the US and 
Canada for nine years I was getting benefits in the UK, and I was still sort of in the health 
system, but I was working the system in both US and Canada and got the best treatment there 
as an undocumented migrant basically, I found ways of getting documentation. But I remember 
Julio Montaner was my doctor in Vancouver, the salvage therapy expert and now “Mr TasP,” 
and he had recommended Mike Youle to be my doctor, and I went to the Royal Free in 2001 
preparing for my move back to the UK to have an initial, it was an audition really, because by 
that time having worked with Julio and learnt to be an expert patient it’s like I wanted…  And 
just before I went in to the appointment I was stopped and they said, “Actually you’re not 
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ordinarily resident, you’re going to have to pay £400 to see Mike Youle.” So I went okay then 
I won’t see Mike Youle. But then I got into the Brighton system and apparently, in the history 
of the Lawson unit in Brighton I have had more resistance tests than anybody as well as 
therapeutic drug level monitoring tests because of the salvage therapy I went through with Julio. 
And it was only in 2001 when I achieved my own undetectable viral load that I actually started 
to appreciate treatment, and that’s when I wanted to write about it, and everything that I had 
experienced and all of the concerns I’d had about side effects and resistance, and TDM and all 
those things I had learnt myself. It was like I need to figure out how to help other people 
understand that. So that was my way in. 
Simon: I like the way you said when they realised that ritonavir could boost saquinavir. So 
because I was doing treatment activism back then some people knew that as soon as saquinavir 
was virtually available. 
Jane A: Well we had grapefruit juice, we used to prescribe grapefruit juice. 
Simon: And so it’s off at a tangent, a geeky little tangent is the history how some of these things 
that we take for granted as medicine actually got accepted, and I can tell you both the companies 
Merck with indinavir, and Abbott with ritonavir, they fought against that data. You had 
someone going from 600 milligrams twice a day to a booster dose of 100 milligrams, that’s all 
you would need, and the option it settled to 400 in each of those companies, but ATP had a 
meeting where we pulled all these people in the room, and indinavir manufacturers would say, 
“No you need 800 milligrams of our drug and just 100 milligrams of the other.” These people 
fought. I’ve got a letter somewhere where I’ve written to the head of my hospital, and got a 
very friendly response back, asking for viral, the importance of viral load tests, and the response 
was that, “It sounds like a very sensible idea but unfortunately we have no randomised clinical 
trial data that supports that.” 
Jane A: But we had a debate, I remember the meeting, about whether we were going to do viral 
loads and, “Shall we or shan’t we?” “I’m not sure it’s worth it,” absolutely those conversations. 
Simon: And those medical things you don’t hear about, Professor Clive Loveday who 
developed the first viral load tests and he was charging the companies £10,000 a kit to test or 
something, or huge amounts of money in order to tell them whether their drugs worked, had an 
application to the MRC to develop viral load technology for individual patient care, and a letter 
came back saying, “There is no circumstances where we could imagine a virus being managed 
Witness Seminar: Antiretroviral Drugs 
Nicholls and Rosengarten (eds.) 
34 
by individual viral load responses,” that sort of interesting stuff, and I’m glad you mentioned 
Mike Youle, Mike Youle I think plays a significant role in why PrEP is even available. To stand 
up in 2002 or 2003 and to Bill Gates say actually, “As a gay man I would quite like to take a 
pill maybe if it would protect me,” and Bill Gates was like a rabbit in the headlights, he just is, 
“Well why wouldn’t you use a condom?” The complete disconnect between a rational way 
about the world works and the reality of the messiness of the way the world works when each 
year a whole new generation of people become sexually active with absolutely no support 
information, and very few resources, and in the context of dynamics about expectations about 
what you’re supposed to do sexually or not do sexually, and how on earth you navigate all that.  
And so these people played key roles, and so I hope you add them to your references. But all 
the lead doctors that came in as junior doctors and thought, “I’m going to go with this and see 
where it takes me.” I don’t know how you people do it, when you take on something where 
there’s no treatment, the numbers of people you have to see. Joseph Sonnabend who is back in 
the UK now, gay man who was a researcher, he was researching, I forget what he was 
researching, I think that will come to me. He was related to basic science research at the MRC 
and ended up working in New York as a doctor where he had a sexual health practice, and 
played a crazily important role in managing for seven years people without treatment and how 
you managed opportunistic infections, and he went on to found things like amfAR and did all 
sorts of things. It was uphill all the way, he doesn’t have good press, didn’t have good press, he 
had to fight all sorts of difficulties. So all the doctors and the nurses that took this on when other 
hospitals were pushing trays under the room, or leaving food outside, or asking that you fly in 
a body bag even though you’re still breathing. 
Ingrid: I was just going to ask a different question but it’s related to, we’ve been talking a lot 
about the science and whether we can trust the science and what we can do without the science, 
and I’ve been thinking about the Swiss statement in 2008. So I was very new to the research 
field, but there seemed to me to be a wholesale rejection of the Swiss statement in 2008, and it 
wasn’t until the RCT HPTN052 that said, “Oh actually, treatment as prevention does work, it 
is a thing, we can think about…” And so I’m interested in your experiences actually of reaction 
to the Swiss statement and reaction to something that wasn’t an RCT, how that played a role 
and how that was negotiated actually, because I did some interviews and there was one man 
who was living with HIV who introduced it to me actually and said, “They’ve said this thing 
about if you’re on your treatment you’re not infectious, I’m not quite sure what to believe about 
that,” and he had been back from the US for a few years, and had been living with HIV, and 
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was really actually struggling with what it meant to be living with HIV at that point, and he 
wasn’t sure how to engage with that information as someone living with HIV. So I wonder 
actually about your engagement with it. 
Marsha: I would like to add to your question if that’s okay, which is that when you say that 
actually people couldn’t accept it until there was an RCT, and I am thinking about, it seems to 
me that what we’re still living in is an amazing experiment, you could say everything is an 
experiment in life, one doesn’t know what will become of things. But from the early days pre-
treatments, and where RCTs weren’t required for what you could do or even determining what 
kind of social research you could do, it seems that now we have become very much regulated 
by a certain mode of evidence making. I am not discounting its contribution, but it does seem 
that actually there’s a lot of inventiveness that went on before treatments - when you talk about 
what did you do in the absence of treatment, like what forms of palliative care or just care. And 
I think care runs all the way through, even how people have done politics, is a kind of caring. 
So I just wanted to expand the question about the response to TasP and the Swiss statement and 
connect it to the response given to every aspect of the epidemic. It has demanded people taking 
risks in thinking as well as taking risks with drugs. I’m just staggered when you say that you 
were in this trial which was a blind trial so you don’t know that actually you’re developing 
resistance while you’re in it. 
Edwin: I think I wrote the first English language story on the Swiss statement, maybe you did 
at exactly the same time Simon, I remember January 30th 2008. It came in French, I was sitting 
in the office at NAM and Sylvie Beaumont who I work with still, Francophone, I remember 
reading it because I have rudimentary French, she translated it, and it was like, “Oh my God, 
they’ve actually said this!” We had known anecdotally about the link between viral load and 
infectiousness for a long time, from the Rakai studies3 from 1999/2000. 
Simon: Rakai was amazing. 
Edwin: And I had written a number of articles for AIDS Treatment Update about the link 
between viral load and infectiousness previously, but the Swiss statement was a huge pivotal 
turning point for us. But I’d like to just talk for a moment about terminology because for me 
the Swiss statement is not about TasP, the Swiss statement was about the individual impact of 
treatment on infectiousness whereas TasP – treatment as prevention – is a policy to me, it’s a 
                                                      
3 This comment refers to a study undertaken in the Rakai district of Uganda, by Quinn et al. (2000). 
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public health policy, and to me they’re very different, and what to me is still remarkable about 
the Swiss statement is this empowerment which of course now lives on in the U=U campaign, 
the empowerment of people living with HIV and what it means to us as individuals living with 
HIV and we feel about ourselves both internalised, anticipated and external stigma, and how 
we feel about not being a risk to our partners. I remember being involved in a number of 
meetings at the WHO and UNAIDS that year, also International AIDS Society I remember 
there was a big pre-conference of the IAS, when was it? It was in Vienna was it? 
Others: Yes. 
Edwin: Mexico, it was Mexico City 2008. A huge debate about that. But later on at the Autumn 
BHIVA conference I remember Bernard Herschel was there, and I presented on the gay men’s 
community response to the Swiss statement, and I framed it through Elizabeth Kubler-Ross’ 
theory of grief, because we were all going through so many different process that there were 
people in denial, there were people bargaining, there were people angry, there were people… a 
few people were at acceptance, but I wasn’t personally, I was still wanting to use condoms for 
many years, probably until HPTN 052 to be honest. So it’s interesting I was in a trial for 
saquinavir, it failed me, but 052 actually gave me the confidence to actually realise that I was 
no longer a risk to my partners (in the plural). So yeah that’s just my experience. 
Matthew: I did a presentation at BHIVA on Friday and I talked about Edwin talking about the 
five stages of grief. I think what’s extraordinary about the whole U=U message, treatment as 
prevention, or however we want to frame it depending on the context, is that it’s taken so long 
to get to the point that we have. I developed a campaign when I was working at GMFA about 
ways that people can reduce the risk even if they don’t use condoms, and it was that very much 
“even if” they don’t use condoms, but at GMFA they would always recognise that gay men had 
their own strategies and we would much rather someone had a strategy which was at least 
partially effective than that they had no strategy whatsoever. So I produced this campaign called 
‘Enjoy Fucking,’ because it’s GMFA, and it said something like, “Most gay men use condoms, 
but not all gay men use condoms, if you choose not to use condoms for whatever reason these 
are things you can do which can reduce your risk of HIV transmission or HIV infection.” We 
actually did three different executions, so one was for people living with diagnosed HIV, one 
was for people who knew they were HIV negative, and one was for people who didn’t know 
their HIV status, and there was not that much text in the one for people who didn’t know their 
HIV status because it’s like, “Well we don’t know what to say to you” [laughter].  
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But on the one for people living with HIV it said that it will reduce your risk if you have a low 
viral load on treatment, and that was in October 2001 that campaign came out, and the Swiss 
statement wasn’t until 2008, BHIVA two years later discussion, and you saying stages of grief, 
and it’s only really in this last year that we’ve seen real traction for that U=U movement. And 
we still see enormous pockets of resistance within HIV positive communities as well as with 
HIV negative communities. I was looking at – back to GMFA – they have just done what I 
think is an excellent video called the Undetectables, and it’s very accessible and funny and 
sassy and great, but if you ever want to feel really depressed go and read the comments 
underneath it on You Tube, because there’s all these comments saying, “Oh well you’re just 
saying that because you want to infect other people, I would never touch a diseased person like 
you, you’re all disgusting and vile” and all this kind of thing, and you go, “God, we have come 
so far” but actually we have still so much yet to journey on this path because of people’s 
attitudes. 
Jane A: But I think the other thing which again going back to the issue of women, we have 
known that women taking antiretrovirals in pregnancy prevented vertical transmission from late 
‘90s, even before and before and before, but it was never computed across the epidemic. So 
pregnant women and their children were in one little box, and that discourse I don’t think went 
across properly, because actually that was something we were promulgating for a small 
population, although again it overlaps with the toxicity of treatment, because the idea that you 
would give an unlicensed toxic drug to a pregnant woman, but the time the professor of 
paediatrics at Homerton said to me, “I wouldn’t give AZT to my dog and you want to give it to 
pregnant women, it’s toxic.” But actually that discourse has coloured the prevention and the 
treatment piece, but actually it worked, and that got itself into reproductive health discourse 
before, or it wasn’t properly acknowledged as being what it was I don’t think. 
Simon: But on that point in Geneva, the AIDS conference in 1998… 
Edwin: Actually it was Mexico. 
Jane A: Geneva was in the ‘80s. 
Simon: No it was 1998, it was in Geneva, it was the first one I went to. So, Karen Beckerman 
from San Francisco had a cohort of 70 women who she treated on the basis of their health 
needing triple combination protease therapy and she reported zero transmissions, and it came 
out just at the same as the UK had found C-section and AZT worked. As an activist group, we 
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brought Karen Beckerman to the UK, and she talked to Body and Soul, and afterwards she had 
50 women, mainly women, in a line to talk to her afterwards about how fantastic this was. And 
unfortunately after the talk to healthcare workers where we thought it would be just as important 
for them to hear this data there was not one question, and the UK guidelines continued saying 
AZT and C-section for at least five years.  
The interest and the response is difficult, and it’s so weird to be in this position as somebody 
who hasn’t gone to university for seven years to become a doctor. It’s interesting how you 
accept knowledge and what is accepted. The Swiss statement was completely refuted, Bernard 
Herschel had a real rough time after this and for years afterwards, and actually HPTN 052 didn’t 
make that much difference because the US CDC only now has said that we see this as something 
that’s important. But behind that there’s a difference between a slight impact on reducing or an 
impact that reduces transmission and actually being able say something doesn’t happen. And 
so it’s very interesting the way that this knowledge took 20 years to settle, and the way that we 
knew that PrEP worked, we knew Truvada or before it was Truvada, tenofovir stopped 
transmission five years before Truvada was even approved, but there wasn’t political will to 
study that as a prevention means, and there wasn’t any interest actually from Gilead who owned 
the drug in studying it as a prevention means. They kicked against it and just about provided 
drug, because politically they couldn’t have not provided the drug. But all those large studies 
were funded by Gates in the NIH, public research funds all this stuff, and then you have the 
fallout afterwards when you see there’s no reflection in the costs that the drugs are charged for. 
Jane A: Isn’t all this going back though to Marsha’s point about risk, and I think there’s 
something really important here, and if I put my healthcare professional hat on first, “Do no 
harm.” I think there’s always been this anxiety about whether you’re going to make something 
worse, and I think that pervades, and it’s getting much more the case. In today’s medical world 
everything is protocolised, you have your list and you tick your boxes, and one of the things 
that I found really, if I think back, the people who were teaching us, as a junior doctor we had, 
“The grown-ups,” they were much more risk accepting, and they allowed risk to happen. Brian 
Gazzard isn’t risk averse, Mike Youle isn’t risk averse, nonetheless we have that sense always 
of, “What could go wrong?” With the Swiss statement, “What if we as doctors tell everybody 
it’s alright and it isn’t?” So there was that kind of, “And what if you give a pregnant woman 
something and the baby comes out all wrong?” I think that has held us back, and it’s getting 
more so, and I think we as a profession are getting much… 
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Simon: But Edwin’s example about most HIV positive people not going anywhere near the 
Swiss statement thank you very much. We have perfectly evolved to have great sex with 
condoms and not put partners at risk, and so there’s… that happens on an individual level as 
well. 
Jane B: I think the whole thing about HIV has been that everybody has lived with uncertainty 
in many different ways. Your example Edwin of how people approached treatment, that 
uncertainty: are you going to get side effects, the community were so full of stories about 
terrible side effects that put people off. But then we always lived with uncertainty about how 
would you advise people anyway, even the simple thing of, “Should I tell my family I am HIV 
or not?” Well we have people who it was really successful with, and we have people who it 
was an absolute disaster.  So that level of uncertainty has been there right from the beginning, 
and I think still when people went into clinic to talk about the Swiss statement or the other 
things people would… the doctors found it difficult to be certain about things, but also there 
was that level of uncertainty from the patients as well. So in and amongst all of that people then 
are prepared to take risk, and that’s unusual for biomedicine because biomedicine doesn’t. Our 
culture of biomedicine is not really risk taking, and that’s what’s been so interesting about HIV. 
Graham: Yes, exactly, it’s so distinctive. So it’s been demonstrated that a new intervention 
that absolutely works takes 17 years to get into practice, that doesn’t happen in HIV, it’s much 
more rapid and iterative… [laughter] 
Graham: Well, PrEP, yeah— 
Jane A: We had to take them to court to get— 
Simon: It takes three years to fix a dripping tap. 
Graham: I think HIV there seems to be much more, let me see, there’s things, ideas that come 
out of the community then turn into scientific questions which are addressed, and this might 
take time but compared to other areas I promise you it’s really quite rapid, and I thought your 
point was really well made about the Swiss statement, about that being about individual 
understanding that you wouldn’t transmit. But that’s quite a different thing from turning it into 
a policy, a public health policy, but it sets off really good science that demonstrates that. Now 
I know that’s slow and it takes a while, but you do need equipoise, you need to be uncertain 
that something is actually the case. If you’re absolutely certain from observational data you 
don’t need a trial, it’s absolutely unethical, you should absolutely go for it. And I believe the 
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first treatments weren’t trialled at all, they were introduced and people started living. So the 
very first treatments were not trialled, they were discovered and it was observational data that 
demonstrate… now then improvements and changes and so on and so forth were trialled later, 
but the early… 
Jane A: But the official data there’s that curve of people stopped dying, and it felt very difficult 
to not do anything other than give AZT in those industrial doses that made everybody deeply 
anaemic and very ill. That curve showed a death rate that went down. 
Edwin: The reason I think that it’s so important to differentiate between the individual benefit 
of treatment on prevention and TasP is because of the dark side of policies around TasP. So 
right now we’re fighting policies in Zambia and a law in Malawi that would actually criminalise 
people with HIV for not taking treatment. I know one thing you want to talk about is what TasP 
and PrEP mean for responsibility for prevention, and I think when we look at the Swiss 
statement and the U=U campaign as being incredibly liberating for individuals, the policies of 
TasP, on the one hand they’re very useful for fighting for universal access to treatment and to 
viral load testing, on the other hand there is this other side of making people with HIV 
responsible again as we always pretty much have been. And that’s why PrEP for me has been 
a revelation working on issues of criminalisation and responsibility because finally there is 
something that someone who is at risk of acquiring HIV takes it.  
So my partner Nick is Germany’s top PrEP activist, has made the Proud documentary and PrEP 
17, he actually wants to have a t-shirt saying, “Your status and viral load is none of my fucking 
business,” and in fact it’s interesting, there’s a lot of work now being done about disclosure, 
the criminalisation of non-disclosure and I just, there was a GMFA article about how best to 
disclose, that is being shared on Facebook. And it makes me cringe a little bit because I don’t 
believe that we need… that disclosure in many ways leads to false sense of security, disclosure 
is a process not a one-time event, all of that. But I think the disclosure, what are we disclosing 
these days anyway?  Are we disclosing I’m positive? If you say I’m disclosing I’m undetectable 
that still means the negative partner needs to trust something that’s completely invisible in the 
absence of condoms. PrEP means that the person who is taking PrEP knows that they are taking 
something that protects them, and I think when you look at how that will translate into policies, 
particularly if that will improve the legal environment for people living with HIV, the jury is 
still out, it’s never been tested in any court yet. But there are lots of people who take PrEP as 
well as use condoms and have a huge fear of people with HIV and acquiring HIV, and I think 
there could still be a complaint from someone taking PrEP that you didn’t disclose and I’m still 
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potentially exposed. So there are just some thoughts about the difference between Swiss 
statement, U=U, and TasP. 
Matthew: I just wanted, to pick up on the disclosure thing because I think I’ve been 
campaigning quite a lot on issues around disclosure, and the reason why I’ve been doing that is 
because I really associate it with the LGBT equality movement, and I think that absolutely 
we’ve made enormous strides forward as a result of people being open about their sexuality, 
and it’s that experience of knowing there are LGBT people in your church, in your barbers 
shop, at your home, in your office, in your family, that has actually really helped push forward 
an LGBT equality agenda, and I think there’s a similar battle to be won in terms of HIV. If it’s 
hidden then people don’t realise what it is and don’t realise that actually treatment can be 
effective and people living with HIV are living full constructive and sometimes messy lives, 
and that’s why I think disclosure is really important. I’m not saying that everyone needs to 
disclose, I certainly would never argue that people should be compulsed to disclose but I think 
people should be supported in disclosing because I think there is enormous social benefit from 
disclosure. 
Edwin: I would just like to say that England is probably the only place in the world where it’s 
legally safe to disclose, because you can only be prosecuted for reckless or intentional 
transmission. In pretty much any other country including in Scotland you’re basically one 
disgruntled ex-partner away from an allegation of non-disclosure and potential exposure. So on 
the other hand of course the visibility is really important, but there’s always two sides, there’s 
always a bright side and a dark side to everything.   
Jane A: Can we just go back to your point about it always being the responsibility of a positive 
person? Because I think this is being played out now. I want to talk about women and PrEP, 
because the whole business of PrEP for women is being promulgated and run and led by women 
living with HIV, and it is those women who have picked up this parcel of stuff and are really 
pushing for it. If you go to the places where women’s health is discussed and you ask about 
how do women feel about taking responsibility for staying HIV negative, that conversation is 
not happening anywhere. So the Royal College of Obstetrics and Gynaecology, women’s 
health, sexual health, the faculty of Sexual Reproductive health are not even beginning to think 
about how women take that responsibility for their own wellbeing, and it’s still the positive 
women’s movement that’s doing that work, and I think we’ve got to change that round. I don’t 
know what the answer is but I still find it quite shocking to not have any of that conversation 
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happening amongst places where women either don’t know their status or are negative, they’re 
not talking about it, it’s somebody else’s problem. 
Graham: I have to go I’m afraid, I’m not walking out but I’ve got a meeting just round the 
corner that I do have to go to. 
Marsha: I don’t know whether people are happy to continue, but I want to say that before you 
go anyway that this has been immensely… it’s been terrific.  We have immensely rich material 
thanks to all of you, and I fully appreciate that we’ve been here for two hours and I feel excited 
that we’ve covered so much [laughter]. It’s been so fabulously… 
Graham: But it’s been so random [laughter]. 
Marsha: I don’t know, I think… 
Simon: You avoided your randomised clinical trial [laughter]. 
Marsha: I think the dots join up, and so it was really great because it wasn’t like, you can read 
a chronology of the epidemic, the presence of AIDS then HIV, identify the drugs, treatment as 
prevention. I really appreciate the distinction that you made, it’s so helpful, and PrEP, and now 
here we are. But actually what we seem to have done is move between medicine, between 
individual experience, between policy, health promotion, we sort of got to drug companies 
briefly, obviously… 
Matthew: We could do two hours on that. 
Marsha: So maybe if Graham if you have to rush off then do please, and I’ll just ask if there 
are other things that people would like to add then before we… 
Graham: Just before I go, I think what you’re saying is absolutely right. There is a, let me see, 
objective chronology of events in HIV which is very clear, and what’s wonderful I think in our 
careers, Jane, is that a disease appeared, treatments came in, and then there is the possibility of 
the elimination which to some people, because, actually because we’ve lived with it for so long 
it feels really weird at the prospect of it going away. But it is possible. But the psychosocial, 
psychosexual dimension of it for those of us who lived through it, and particularly friends, 
colleagues here is actually it’s not that series of very clear events, it is as the conversation has 
gone on it’s actually, I’m still living with some of my early feelings about it, and it hasn’t gone 
away in that sense. So I just feel that there are the narratives that are really important, because 
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they’re not purely historical and neat, there’s a lot of mixed things going on there. So anyway 
that’s all I wanted to say. You made me remember that. 
Jane B: One thing I would like to say about when drugs first came in, and it goes back to that 
issue about certainty and uncertainty. Before effective drugs came in, obviously there was a 
degree of certainty about how patients would be managed in terms of that holistic approach to 
care, because it was care and there wasn’t that sense of cure. And so decisions about 
withdrawing treatment and moving to palliative care, those decisions were easier because it was 
a decision with the patient, with the doctors, with the nurse, that non-hierarchical level playing 
field really, and very much about the individual decision, and involving people in those 
discussions, by and large, obviously sometimes that wasn’t always so easy. But when treatment 
came in all of that got turned upside down, a good thing, I don’t want to sound negative, but it 
nevertheless it made decisions about who to start on antiretrovirals, when to stop if it wasn’t 
working and people were going to die, and so all that certainty we had about how we were 
caring for people became much more uncertain because you didn’t know what was going to 
happen.  
We saw people with terrible side effects, and so it was that period that I found very challenging 
as a nurse in particular, and it affected particularly, the hierarchy seemed to change, and I think 
that traditional role of the doctor is the father, the nurse is the mother, and the patient is the 
child, which we’d ditched, and got that equal relationship, seemed to slightly come back, 
because of the hierarchy of knowledge, and the power of knowledge, which was invested in a 
smaller number of people. Which to a certain extent because it excluded some of the patients 
very much as well I think in terms of what their knowledge was about drugs and what was 
happening, because it was all quite quick, I suppose. So I think that’s something to think about, 
it links into that concept of moving away, to a certain extent, from that individualised care, and 
the responsibility the patient had about their care. So it’s one of the things that we’ve had to 
live with and work through I think to get back to perhaps patients being more involved in the 
decisions about their care. 
Jane A: And I have a very strong memory, you’ve triggered something I hadn’t thought about 
for a long time, I remember being taught early on, that if you don’t know how you’re going to 
stop the antiretrovirals then be very careful how you start them. Because you knew that some 
people were going to have to stop, there would be a stop somewhere because something 
happened. 
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Simon: I like your reflections on that, it’s very interesting, and it has reversed the other 
direction. Now you have five minutes and in the five minutes you will get your prescription or 
not. 
Jane B: And it becomes more and more about, so it’s that thing about what’s after undetectable? 
The whole focus and psychosocial issue has become less important. 
Simon: It was in the context of all these positive responses. We live in an amazing time, but I 
still do treatment workshops and training and all those sorts of things, and most of my training, 
at one point it was giving people the option of where they saw themselves in a model of care, 
if the doctor was at the top of the pyramid, “Does this feel like what you’re in?” And all the 
hands went up. And I said, “But what about this model where there’s these things around the 
circle, and you’re in the middle of care because it’s about your health?” And nobody felt like 
that, and it wasn’t scientific, it was just, “How do you feel about your structure of care?” And 
for all that work in developing different models of healthcare and how we translate knowledge 
and pass on knowledge and make people empowered hasn’t really worked through, and we’re 
going against that with the cuts in funding for the NHS, it’s getting very much more difficult. 
Jane B: Because we assessed people using that model when they came into Broderip, we would 
have the patient in the centre, and ask them who is in that circle. 
Edwin: It’s so interesting because on a global level, I was working with the Global Network of 
People Living with HIV on a person-centred policy called Positive Health, Dignity and 
Prevention which is the nicer way of talking about positive prevention or prevention policies, 
which is very much about the person here in the centre holistic model where treatment is only 
one part of it. And there’s now, because we’ve moved to this incredibly medicalised model both 
for treatment and now potentially for prevention, there’s this now policy the International AIDS 
Society is leading called Differentiated Care, which is basically this idea that instead of 
everyone just following WHO guidelines which is a public health approach and everybody just 
takes everything first line and then everything second line, differentiated care is again trying to 
move to a more individualised model. And again we haven’t learnt from the fact that of course 
people living with HIV and people at risk of HIV if they’re going to be on PrEP need to be at 
the centre of our care, and needs to be holistic approach, because in the end we’re relying on 
adherence.  
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We don’t have to be expert patients anymore, we still need to understand what it means to take 
pills every day and to also deal with the stigma that’s associated with those pills, whether you 
have HIV or whether you don’t, and then all the socioeconomic and cultural issues. And so 
we’re going round in circles again, and it’s interesting to have a nostalgia about the time before 
treatment when the patient was at the centre but of course many of us were dying, and we have 
to balance that with this idea that we’re not. But that’s, to me, when talking about the impact of 
treatment on larger policies, which is my concern these days, HIV criminalisation really only 
began to have a huge traction once post-96, even actually 21st century of course, Scotland had 
a first prosecution 2001, England 2003, and even though there had been laws and prosecutions 
previously, particularly in the US and Canada and a few in Australia, it’s this idea that we are… 
this move culturally from us being patients and to have sympathy for us, because actually 
there’s no point worrying about what we might do in the future because we’re likely to die. The 
moment we all came back to life we started to be seen by society and particularly by law and 
policy makers as threats to society, and that’s why HIV criminalisation is growing even now, 
even in the context of treatment and treatment as prevention, and that’s why I’m constantly 
alert to the punitive approach of treatment as prevention because on the one hand we’re all very 
excited about what the impact of U=U and the Swiss statement might have on individual cases, 
and people are able to use those as defences, we’ve been highlighting this for many years. The 
Swiss statement was written primarily to help in defence of criminal cases, because you 
couldn’t consent to condomless sex in Switzerland, and so people were being prosecuted even 
despite the partner having consented. And we’ve seen that rollout in Canada and in Sweden, 
Australia, and now we’re working together with UNAIDS, the IAS and IAPAC on a globally 
relevant consensus statement on science in the context of criminal law.  
But we are very mindful of the fact that so many people don’t have access either to treatment 
or to viral load testing, that we’re not going to say that the only defence is if someone is on 
treatment and they know they have an undetectable viral load to risk. So HPTN 052 wasn’t 
about viral load it was actually about treatment, it was that people on treatment after a few 
months that basically didn’t pass on HIV to their partners and phylogenetics showed that any 
HIV acquired in that study was actually from sex outside partners. So I think it’s really 
important to make sure that we understand that the culture of treatment and treatment as 
prevention, I keep saying it has this positive side. It’s amazing we’re all alive and doing well, 
and we can look at the potential of the end of AIDS as UNAIDS likes to call it by 2030, or the 
end of AIDS as an epidemic or HIV as an epidemic by 2030. But I think there are more… I 
have more concerns now, I think the stigma of people who are not on treatment and who are 
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not undetectable is actually worse now than ever, and I have concerns about the religious 
fervour around the U=U campaign, despite it being amazing and empowering for lots of people, 
I think it really can have a negative impact on people who have not been able to achieve 
undetectable for whatever reason, who don’t have access to viral load testing, and it creates this 
other division of there’s ‘good’ people with HIV and there’s ‘bad’ people with HIV. And that’s 
something that’s happened throughout the epidemic, and it seems to be perpetuating even now. 
Simon: I probably should add a caution that all my pharma references shouldn’t all be negative 
[laughter] these other guys, people that developed the treatments by and large. But also as 
companies they are not unified, there’s different pools that happen within industry and we’ve 
all had to… my first idea that I had to learn the name of drug companies when I started working 
on the ATP phone line was crazy, how do you pronounce Boehringer Ingelheim, and why 
should I know about it other than the fact I might get some funding, or I might lose some 
funding. So my first published article was about saquinavir and the Roche funding disappeared 
overnight because it was titled ‘is saquinavir safe?’ And it clearly wasn’t safe, people weren’t 
getting the right dose. Sometimes you get away with things as a community person, activist or 
whatever you call it, that you know is not going to be said in other settings, if everybody else 
is being funded by someone, sometimes you can say something without worrying about that. If 
your career in the NHS is dependent on what the person at the top thinks about you, maybe you 
won’t challenge their decision to randomise everyone to just dual therapy or something crazy. 
Or to save a bit of money we’ll put everyone on forsamprenavir which are all real examples, 
we’ve been in meetings where that has been suggested. And so that balance is interesting, and 
I’ve also met the scientists generally that work at companies, and lots of the other people that 
work in companies are really targeted on. They got there because they can see a way of making 
the world better, and they’re smart people and they did well at school, and now they’ve got the 
prospects for doing research and developing drugs there’s very few places where you can do it. 
The marketing approach for what happens and how this good intention becomes a monster is 
completely different, and it does become a monster.  
I’ve just been at a meeting on Tuesday, which was about this interface about drug pricing and 
drug costing and how it does it, and regulation and the EMA are looking at whether you don’t 
really need randomised data, whether there’s a faster pathway, all being promoted by a cheaper 
way of developing drugs, or not drugs, but just saying, “Here we have something and would 
you like to try it on the basis of very little evidence?” In the US the dynamics for reducing 
regulations for drug approval is serious, that’s the way it’s going, you will not have good data 
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on the way it’s going. But somebody from a company there stood up and justified the price of 
new hepatitis C drugs as potentially being cost saving. There is… and you can’t price… drugs 
have to be priced at certain, at levels that healthcare systems can afford, and you can’t twist it 
around and say that in this one person if you’re not going to give them a liver transplant because 
actually it’s much cheaper to give them this drug, those are crazy, and that dynamic is the way 
the companies are being driven, it’s because governments allow them to get away with it and 
regulators allow them to get away with it, and there is no cap pricing on there, and that’s a really 
negative side of that particular industry. It’s not across the board. 
I remember when treatment first came and I was working at a group of the African activists 
there in terms of HIV denial, they say, "Listen we went through this, we learnt if you see 
someone who is ill" – it was Hope Mhereza actually – "Your village sees someone who is sick 
and you kill a chicken, but then somebody else would get sick and you kill another chicken, 
you learn soon that the killing of the chickens isn’t going to help with this health complication 
you have". But when treatment came, THT who have done fantastic work and provided amazing 
services, I should add to that as well, there was definitely a move where the buddying system. 
The buddies were really upset that their services weren’t being used, and they fought to have 
this service continued in the lack of need, because it was remarkable. You got good treatment, 
you get on with your life, and that was where being an active patient made a big difference, and 
I’d argue it still makes a big difference now, unfortunately we still get cases where people fall 
through the cracks, they’re on inappropriate treatment. Sometimes it’s not any conspiracy 
theory it’s just the messiness of stuff, and so having people from different specialities being 
able to get involved I think is really positive, and you started with being a model for other health 
areas, it definitely is I would hope. 
Edwin: You know there’s this movement in the US to recognise long term survivors, and 
there’s the Kick ASS, the long term “AIDS Survivor Syndrome,” and there’s been a number of 
activists in the US who stopped taking drugs or did chemsex and died, is that something that 
happens here too? Because although I had a nervous breakdown for a few months coming to 
terms with what happened to me and then moving on, I’ve always wanted to live, is that 
something that we know much about in the UK, have we lost people recently who we know as 
long-term survivors because for whatever reason they have just given up the fight? 
Simon: I don’t think in a big way, but we still get people contacting us who don’t see any open 
doors, they don’t see any avenues for their life to get better unfortunately, and sometimes they 
get to that point because they haven’t had the opportunity to be aware of some of this stuff that 
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we take for granted if you’re connected in terms of advances and knowledge and treatment, all 
those sorts of things. So it does, HIV still has an impact that it does push you… can push you 
towards a community response and a network, but it can also for more people I think it pushes 
you down to a smaller world and a more narrow set of options. Most people still close doors, 
they make decisions about, we still have people who think they can’t have children. I gave a 
talk in Manchester a year ago and the women there were saying, “You mean I can have 
children?” And that was just heart-breaking. And so unfortunately there’s lots of stuff that is 
really helped by people having a public profile. 
Edwin: We’re talking about the long-term impact of taking care of people with HIV, that people 
have died, really important people, and in response have taken their own lives and I’m just 
wondering if that’s something we need to recognise or think about. I’m sorry to end on a downer 
but it’s like I think the legacy of this history, we’re all living with it still. 
Marsha: And it makes me think of Primo Levi who was the extraordinary author about the 
Nazi genocide who then much later in life committed suicide, and one doesn’t ever know really 
what produces that particular act or happening of suicide. But I think it’s easy to assume that 
there’s a certain temporality and that things just move on positively rather than some things 
catch up with you at certain moments.  But I think, I’m not into psychoanalytic theory but how 
we understand the epidemic is a history of trauma in lots of ways, isn’t it? And yet we have got 
these technologies and there’s incredible practices that have changed doctor patient relations 
and organisations, and information, and so on, that I often think about. In fact, on Monday I 
showed this set of slides that William Yang who was an Australian photographer did of 
somebody dying, a close friend dying of AIDS, I showed them to my students and I’ve shown 
this for years, and every time I just start crying, which I think maybe this is good for my second 
year students to see that this is… that it’s incredibly moving. But I’m staggered that I still have 
this emotion, and just there. 
Simon: So there’s big issues. In a way, HIV was so bad that it prompted a whole set of 
responses, a lot of which were quite amazing really. But there’s similarly huge areas which as 
a society are completely neglected, mental health is one of them, and psychological health and 
wellbeing are other ones, ageing is another one, ageing will push you to be isolated unless 
you’re very lucky and have a good network and you work on it and you have thousands of 
grandchildren running around making sure you don’t make a fool of yourself. I think these are 
big issues where you can overlap some of those experiences and learn from them, and then 
people have the potential. All sorts of things in life push you away from your potential, 
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including self-policing or deciding, “That’s not for me,” or “I’m not clever enough to do this,” 
or, “Maybe I shouldn’t do that,” or, “Maybe I shouldn’t behave because somebody will think 
that way,” and I think all the points you raised are valid. 
Edwin: I was steeling myself for this meeting, and I think I’m going to have to take some time 
to process it too, because there’s an awful lot of things that I have buried, it’s not like I haven’t 
necessarily thought about these things but to hear them also as a communal experience is quite 
special, and I’m keeping it together right now, but I’m sure I’m going to go and lock myself in 
a bathroom and cry very soon, because this has really quite been an intense conversation, and I 
feel so remarkably privileged to have lived through it all and survived as well, because that’s 
what continues to motivate me to be an activist. And I think it’s so important to honour all the… 
I can’t even imagine what it must have been like for you [Jane A and Jane B] to care for so 
many people and die, to see them die. I have only lost maybe scores rather than hundreds or 
thousands of people that you probably knew, but this must be an emotionally fraught thing, 
because we’re all human even if we’re all professional. 
Jane B: You talked about the dark and the light and I suppose that’s what I have experienced 
throughout my time in HIV is there has always been that light there, whether it’s the people you 
have nursed and you’ve nursed to a good death, or the people who you’ve worked with who 
have been inspirational, and it seems to for me personally it’s that kept a certain balance and 
probably why I’m still here and interested and want to share those experiences I think. That’s 
not to say it hasn’t been hard but there is a balance, there does seem to be a balance, and the 
fact that people like yourself are still here, that is just an amazing thing, and there have been 
obviously lots of people who are not here. Yeah, it’s a journey that’s been very up and down 
that seems to have been balanced. 
Jane A: I think it’s been really interesting because there’s this flurry of these sorts of looking 
backs recently, and I don’t think I realised when I was in it what I was in. I think I realise now. 
I think at the time you do what you do, and it was extraordinary and all sorts of things which I 
recognised at the time but there’s loads more I’m looking back, thinking, “Blimey, I hadn’t 
looked at that like that before.”   
Jane B: This has been amazing though, this has been extraordinary to be in a conversation like 
this with people from many different backgrounds and yeah, it’s been really thought provoking. 
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Jane A: It has, I agree with that, and hearing the same thing from different… somebody seeing 
it from the other side. 
Marsha: So that says something about the epidemic itself, doesn’t it? I don’t know what else, 
what other condition could have a group of people and this conversation about the experience 
of it. But I was thinking what about what Simon was saying about drug companies and how to 
think about how there are scientists in them who are working really hard and doing their best, 
but also you’ve got the market and so on, and I was thinking about the connectedness of these 
things to what matters in the experience of HIV. Because sometimes when I’m talking to my 
positive friends about PrEP and the debates and so on, I’m conscious that their experience is 
made absent in the nature of the conversation and I think it’s right what you were saying Jane, 
about the how do you… that it’s positive women who are talking about PrEP for negative 
women, I think a lot of work is done by positive people in this epidemic. I don’t know, there’s 
something about the presence of the virus that’s very hard to… I don’t think words are adequate 
to capture it, maybe other art forms can do that work and we don’t have much of that anymore. 
I feel a bit frustrated with the academic response to it, the risk of turning things into academic 
work. 
Jane A: I was thinking as you’re talking a word that’s coming and it sounds incredibly soppy 
and I’ll probably take it out when you send the transcript, but there’s something about love that 
comes out of all this, and the fact that so much of this whole thing is about people being in love 
with each other, and there is a connectedness, and I don’t know whether it’s something to do 
with the fact that it’s all bound up with emotion and people’s love for each other, and sex has 
led to all sorts of other complications, and then you end up in a situation with no drugs that 
you’re caring. There’s something which I don’t think happens in other bits of medicine, because 
you’re not tapping perhaps into that bit of life, people’s… just somehow, I haven’t got proper 
words for it but I think there’s something about emotion in there.  
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APPENDIX  
PROPOSED D ISCUSS ION TOP ICS CIRCULATED P RIOR TO SEM INAR  
 
• HIV Pre-1996 
o Monotherapy 
o Clinical trials 
• XI International AIDS Conference 1996, Vancouver 
o Responses 
o Availability and rollout of combination therapy 
o How/what it changed for medical practice, care, advocacy and activism 
• Access to treatment and treatment activism 
o Patient involvement 
o The circulation of information regarding ARVs 
• Treatment as Prevention (TasP) 
o The science 
o What new questions or problems did TasP raise? 
o If/how TasP changed activism, advocacy and the role or form of prevention 
efforts/campaigns 
o If/how TasP changed notions of responsibility 
• Pre-Exposure Prophylaxis (PrEP) 
o The science 
o Activism 
o Resistance 
o The future 
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